Paul Orchard is an Oncology physician affiliated with University of Minnesota. OpenAlex indexes 427 publications with 17,484 citations (h-index 63); ClinicalTrials.gov lists 19 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Pediatric Hematology-Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
516 Delaware St SE
Pwb Fifth Floor, Suite 5-100, Clinic 5b
Minneapolis, MN 554550356
Telephone
612-626-2663Registry record last updated 26 Oct 2012.
Clinical trials
- Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.
Sponsor: Masonic Cancer Center, University of Minnesota
- Early Diagnosis Of Childhood Cerebral ALD
Sponsor: Masonic Cancer Center, University of Minnesota
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Orchard Therapeutics North AmericaProgram year20259 payments
- GENZYME CORPORATIONProgram year20246 payments$20,594openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2003–2009 per NIH RePORTER. The latest:
- CLINICAL TRIAL: PHASE II STUDY OF COMBINED LARONIDASE (ALDURAZYME) ENZYME REPLAC
University of Minnesota
FY2009$8,416M01RR000400 - CLINICAL TRIAL: PHASE II STUDY OF COMBINED LARONIDASE (ALDURAZYME) ENZYME REPLAC
University of Minnesota
FY2008$8,392M01RR000400 - PHASE II STUDY OF COMBINED LARONIDASE (ALDURAZYME) ENZYME REPLACEMENT THERAPY (E
University of Minnesota
FY2007$3,740M01RR000400
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy
New England Journal of Medicine
2024 - Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy
Biology of Blood and Marrow Transplantation
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Blazar, MD
University of Minnesota
Jay Cohn, MD
University of Minnesota
Julia Steinberger, MD
University of Minnesota
Charles Herzog, MD
University of Minnesota
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”